Cargando…

Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma

Patients with pancreatic carcinoma are at an increased risk of venous thromboembolism (VTE), which is a major cause of morbidity and mortality in various types of cancer. The aim of this study was to determine the incidence and clinical significance of VTE in patients with pancreatic carcinoma, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kondo, Shunsuke, Sasaki, Mitsuhito, Hosoi, Hiroko, Sakamoto, Yasunari, Morizane, Chigusa, Ueno, Hideki, Okusaka, Takuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908292/ https://www.ncbi.nlm.nih.gov/pubmed/29682191 http://dx.doi.org/10.18632/oncotarget.24721

Ejemplares similares

A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Sasaki, Mitsuhito, et al.
Publicado: (2021)

A retrospective analysis of factors associated with selection of end-of-life care and actual place of death for patients with cancer
por: Kondo, Shunsuke, et al.
Publicado: (2014)

Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study
por: Iizumi, Sakura, et al.
Publicado: (2019)

Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial
por: Terazawa, Tetsuji, et al.
Publicado: (2014)

Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy
por: Kondo, Shunsuke, et al.
Publicado: (2012)

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma
por: Shiba, Satoshi, et al.
Publicado: (2012)

The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Germline mutations in cancer-predisposition genes in patients with biliary tract cancer
por: Terashima, Takeshi, et al.
Publicado: (2019)

Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis
por: Mayahara, Hiroshi, et al.
Publicado: (2012)

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials
por: Koyama, Takafumi, et al.
Publicado: (2019)

Clinical characteristics of pancreatic and biliary tract cancers associated with Lynch syndrome
por: Takamizawa, Shigemasa, et al.
Publicado: (2021)

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort
por: Okusaka, Takuji, et al.
Publicado: (2023)

Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma
por: Kondo, S, et al.
Publicado: (2013)

The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Correction: The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial
por: Ito, Tetsuhide, et al.
Publicado: (2012)

Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma
por: Hagihara, Atsushi, et al.
Publicado: (2014)

First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2018)

Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives
por: Hijioka, Susumu, et al.
Publicado: (2021)

The incidence of venous thromboembolism is not lowin Korean patients with advanced pancreatic cancer
por: Yoon, Seug Yun, et al.
Publicado: (2018)

Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis
por: Okusaka, Takuji, et al.
Publicado: (2023)

Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer
por: Takai, Erina, et al.
Publicado: (2015)

Germline mutations in Japanese familial pancreatic cancer patients
por: Takai, Erina, et al.
Publicado: (2016)

Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
por: Ito, Tetsuhide, et al.
Publicado: (2013)

Erratum: The incidence of venous thromboembolism is not lowin Korean patients with advanced pancreatic cancer
Publicado: (2018)

Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreaticobiliary Cancer Aiming for a Comprehensive Genome Profile
por: Hijioka, Susumu, et al.
Publicado: (2023)

Hematocrit and incidence of venous thromboembolism
por: Folsom, Aaron R., et al.
Publicado: (2020)

Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines
por: Sakamoto, Yasunari, et al.
Publicado: (2019)

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer
por: Okusaka, T, et al.
Publicado: (2004)

The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan
por: Yamamoto, Shun, et al.
Publicado: (2022)

Author Correction: The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan
por: Yamamoto, Shun, et al.
Publicado: (2022)

Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer
por: Ohmoto, Akihiro, et al.
Publicado: (2019)

Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry)
por: Ohashi, Yasuo, et al.
Publicado: (2018)

Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines
por: Okusaka, Takuji, et al.
Publicado: (2020)

Endoscopic ultrasound‐guided choledochoduodenostomy without fistula dilation using a stent with a 5.9‐Fr delivery system: Comparison to a conventional procedure with fistula dilation
por: Koga, Takehiko, et al.
Publicado: (2021)

Phase II study of S-1 in patients with advanced biliary tract cancer
por: Ueno, H, et al.
Publicado: (2004)

Venous thromboembolism and sarcoidosis: co-incidence or coexistence?
por: Goljan-Geremek, Anna, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tnfoknflbqerqgmqv8q6o1jg25